Severe Mental Health Risk and Your Genetics

Severe Mental Health Risk & Genetics | ExomeDNA

Research into the genetic underpinnings of severe psychiatric conditions has accelerated considerably over the past decade. Large-scale genome-wide association studies (GWAS) now point to hundreds of common genetic variants that, in aggregate, contribute to statistical differences in population-level risk for conditions such as psychotic and mood spectrum disorders. The polygenic risk score (PRS) that ExomeDNA computes for this trait summarizes that cumulative signal — but it describes statistical background at a population level, not individual destiny. Environmental influences, life experience, access to care, and developmental context shape outcomes in ways that no genetic readout can capture alone.

What is Severe Mental Health Risk?

The phrase "severe mental health risk" as used here refers to the aggregated polygenic signal associated with conditions broadly classified as serious psychiatric disorders — primarily psychotic-spectrum and major mood disorders. These include schizophrenia, bipolar disorder with psychotic features, and related presentations. Population-level lifetime prevalence estimates for these conditions are relatively low: schizophrenia affects roughly 1% of the global population, and bipolar disorder approximately 1–2%. Because population base rates are low, even a meaningfully elevated polygenic score translates into only a modest shift in absolute risk for any individual person.

Polygenic risk scores for psychiatric conditions are research constructs. They are not clinical tools. A score in a higher percentile range reflects that a person's inherited variant profile more closely resembles profiles seen, on average, among individuals in affected cohorts in large research studies — not that any particular outcome is predetermined. The same caution applies to a low score: the absence of elevated genetic signal does not confer immunity, and the majority of people who develop severe psychiatric conditions do not have dramatically elevated PRS values.

Related traits on ExomeDNA worth reading alongside this page include schizophrenia genetic risk factors, bipolar disorder polygenic risk, and depression and genetic predisposition.

The genetics behind Severe Mental Health Risk

The genetic architecture of severe psychiatric conditions is profoundly polygenic. No single gene causes or prevents these conditions. Instead, hundreds — and by some estimates thousands — of common variants each contribute a tiny fraction of statistical variance. The aggregated signal across these variants constitutes the polygenic risk score.

Among the genes implicated in recent large-scale GWAS for severe psychiatric outcomes, several are highlighted in ExomeDNA's authorized gene set for this trait. GRM1 encodes metabotropic glutamate receptor 1, a protein expressed broadly in neurons throughout the brain. GRM1 plays a central role in glutamatergic neurotransmission, and the glutamate hypothesis has become a major mechanistic framework for understanding psychotic-spectrum disorders. Dysregulation of glutamate signaling has been observed in postmortem and neuroimaging studies of affected individuals, and GRM1 sits at a plausible biological intersection between genetic signal and observed neurobiology.

ESR1, the estrogen receptor alpha gene, mediates estrogen signaling within the brain. Its inclusion in the genetic architecture of severe psychiatric conditions is consistent with the well-documented sex differences in onset timing, symptom presentation, and course of conditions such as schizophrenia — where males tend toward earlier onset and females toward a second peak of vulnerability around the perimenopausal period. ESR1 variants may contribute to these epidemiological patterns through effects on hormonal modulation of neural circuits.

ATP10A encodes a P4-ATPase lipid flippase involved in translocating phospholipids across the membrane bilayer. It is expressed in brain tissue and is thought to contribute to membrane asymmetry maintenance, a process with implications for neuronal signaling and synaptic function. COPRS, the coordinator of PRMT5 and differentiation stimulator, is involved in transcriptional regulation and cell differentiation pathways. Both genes represent the kind of regulatory and membrane biology signals that emerge from large-scale GWAS efforts — biologically plausible, but with effect sizes that are individually very small.

Other authorized genes in this trait's panel — including CTPS2, FAM187B, FXYD5, HERPUD2, HLX, HS3ST3B1, and COPRS — contribute to the overall polygenic signal. Each represents a statistical association from large population cohorts rather than a deterministic mechanism, and the science of interpreting their combined effects continues to evolve.

What the research says

The four studies forming the primary evidence base for this trait each contribute to the growing body of psychiatric GWAS literature. See ExomeDNA's methodology page for a full description of how we evaluate and weight research evidence.

Galfalvy and colleagues (2015) conducted one of the earlier GWAS efforts focused on suicidal behavior as a heritable phenotype, identifying loci that partially overlap with broader severe psychiatric risk architecture [1]. Otsuka et al. (2019) extended this work into a Japanese population cohort, identifying polygenic effects in a non-European sample — an important step given that most early psychiatric GWAS were conducted in European ancestry cohorts [2].

A 2020 study by Docherty and colleagues analyzed genetic data from over 3,500 individuals who died by suicide and found that polygenic scores derived from the analysis were associated with several clinical antecedents, including mood and psychotic disorder presentations — underscoring the shared genetic architecture across severe psychiatric presentations [3].

Docherty et al. (2020) conducted a genome-wide association study of suicide death and examined polygenic prediction of clinical antecedents, finding meaningful overlap between the genetic architecture of severe psychiatric conditions and extreme outcomes [3]. Li et al. (2022) performed a large meta-analysis aggregating data across multiple cohorts to improve statistical power and identify more robust loci [4].

The Li et al. (2022) meta-analysis included data from tens of thousands of participants across multiple ancestry groups and identified several genome-wide significant loci, while also demonstrating substantial genetic correlation between suicidal behavior phenotypes and major psychiatric disorders including schizophrenia and bipolar disorder [4].

An important limitation acknowledged across this literature: PRS derived from these studies explains only a modest fraction of variance in outcomes at the individual level. Heritability estimates for severe psychiatric conditions range broadly in the literature, and the gap between population-level GWAS findings and individual-level clinical prediction remains substantial. These scores should not be used to make individual predictions, and researchers continue to refine the methodology.

Research base: Robust.

How Severe Mental Health Risk affects you

A polygenic risk score for severe mental health risk does not indicate whether any individual will experience a severe psychiatric condition. It reflects where a person's inherited variant profile sits relative to distributions observed in large research cohorts. The overwhelming majority of people — including those with elevated scores — do not develop severe psychiatric conditions, and many who do have scores near the population average.

What genetics can offer in this domain is a window into statistical background. Someone with a higher polygenic score has a variant profile that, in aggregate, more closely resembles profiles seen at higher frequency among individuals in affected cohorts. That is a probabilistic signal, not a clinical prediction. Environmental factors — early life stress, substance use, urban environment, trauma exposure, social support, and access to mental health care — are among the many non-genetic contributors to whether and how psychiatric conditions manifest.

For most people, reviewing a genetic result in this category is unlikely to be immediately actionable in isolation. General principles of mental health maintenance — regular sleep, physical activity, strong social connections, and early engagement with mental health professionals when distress arises — are supported by broad evidence regardless of genetic background. If this result raises questions or concerns, speaking with a mental health professional or genetic counselor is a reasonable next step.

It is also worth noting that the genetics of resilience and recovery are an active area of research. Genetic background is one layer of a complex system, and the same variant profile that contributes to one pattern of vulnerability may intersect with treatment response, coping capacity, or environmental buffering in ways that science is only beginning to understand.

Working with your Severe Mental Health Risk profile

Engaging with a polygenic risk result in a sensitive domain requires a particular kind of context. A result in this category is best understood as one data point in a much larger picture of mental health, not as a forecast. For most people, the practical value of this information lies less in any specific action and more in fostering awareness of general mental health maintenance and the importance of early help-seeking.

If someone has personal or family history of severe psychiatric conditions, that family history is itself a meaningful signal — and one that has long been used in clinical genetics and psychiatry. A polygenic score adds statistical granularity to a picture that a clinician or genetic counselor can help interpret in context. ExomeDNA strongly encourages anyone who finds this result concerning or confusing to discuss it with a qualified professional rather than interpreting it in isolation.

Mental health conditions, including severe ones, are treatable. Early identification, consistent care, and evidence-based interventions significantly alter outcomes. The genetic signal captured in this trait does not change the fundamental message that mental health is dynamic and that circumstances, support, and treatment matter profoundly.

Research into related traits may also provide useful context. Exploring anxiety sensitivity and genetic background and sleep chronotype genetics can help build a more complete picture, since sleep disruption and anxiety sensitivity are frequently co-occurring features across the psychiatric spectrum and are themselves polygenic traits with actionable lifestyle dimensions.

Related traits and genes

The genetic architecture of severe psychiatric conditions overlaps substantially with other traits in the Brain & Mental Health category. Schizophrenia genetic risk shares a significant portion of its polygenic signal with the severe mental health risk trait — this genetic correlation reflects the biological overlap between psychotic-spectrum conditions that has been documented across large cross-disorder GWAS efforts. Bipolar disorder polygenic risk similarly shows genetic correlation with this trait, consistent with the dimensional rather than categorical nature of psychiatric genetics. Depression and genetic predisposition rounds out the closely related set.

Across categories, sleep chronotype and anxiety sensitivity are both polygenic traits with documented associations to psychiatric outcomes in the literature. Disrupted circadian rhythms are a transdiagnostic feature across mood and psychotic disorders, and anxiety sensitivity is a dimensional trait that overlaps with vulnerability to several internalizing conditions.

The genes highlighted in this trait — particularly GRM1 and ESR1 — appear in related psychiatric trait literature as well, reflecting the shared biological pathways that cut across traditional boundaries. ATP10A's brain-expressed membrane biology and COPRS's transcriptional regulatory role place them in a broader network of neurobiological processes implicated across the psychiatric spectrum.

Frequently asked questions

Does a high score on this trait mean a severe psychiatric condition will develop?
No. A polygenic risk score describes statistical background at a population level. The majority of people with elevated scores do not develop severe psychiatric conditions, and genetics represents only one layer of a complex, multifactorial picture. Environmental, developmental, and social factors all play significant roles.

Can this genetic result be used to make clinical decisions?
No. Polygenic risk scores for psychiatric conditions are research tools, not clinical predictors. They are not validated for individual clinical decision-making and should not be used to make treatment or management decisions. Anyone with clinical concerns should consult a qualified mental health professional or genetic counselor.

What genes are included in this trait?
The genes represented in ExomeDNA's severe mental health risk trait include GRM1, ESR1, ATP10A, COPRS, CTPS2, FAM187B, FXYD5, HERPUD2, HLX, and HS3ST3B1. Each contributes a small statistical signal to the overall polygenic score. No single gene determines risk.

How reliable is the research behind this trait?
The research base is rated Robust, reflecting multiple large-scale GWAS studies across diverse populations with replication across cohorts. However, the ability to translate population-level findings to individual prediction remains limited — a fundamental constraint of current polygenic score methodology across all psychiatric traits.

What should someone do if they find this result concerning?
Speaking with a mental health professional or genetic counselor is the most appropriate step. They can help interpret the result in the context of personal and family history and provide guidance tailored to individual circumstances. General mental health maintenance practices — consistent sleep, social connection, physical activity, and early help-seeking — are broadly supported regardless of genetic background.

Does a low score mean there is no risk of severe psychiatric conditions?
No. A low polygenic score does not confer immunity. Many people who develop severe psychiatric conditions have scores near the population average. Environmental factors, trauma, substance use, and other contributors play major roles that are not captured by a genetic readout.